Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2018 Filed Aug 2, 2018 16:26 UTC |
Rutherford ColinDirector
|
GrantStock option (right to buy) · Derivative | 0 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001618835-18-000080 · wf-form4_153324159921960.xml · derivative · entry 1 Rutherford Colin · CIK 0001726264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,550 Underlying: Common Stock · 5,550 shares Expires 2028-07-31 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from July 31, 2018. The option was awarded in connection with Mr. Rutherford's board and committee services. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:25 UTC |
File Justin J.Chief Financial Officer
|
GrantStock option (right to buy) · Derivative | 0 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001618835-18-000079 · wf-form4_153324153509644.xml · derivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,000 Underlying: Common Stock · 114,000 shares Expires 2028-07-31 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from July 31, 2018. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:20 UTC |
PELLETIER SAUNDRA LDirector · Chief Executive Officer
|
GrantStock option (right to buy) · Derivative | 0 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001618835-18-000075 · wf-form4_153324118436415.xml · derivative · entry 1 PELLETIER SAUNDRA L · CIK 0001251371 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,500 Underlying: Common Stock · 313,500 shares Expires 2028-07-31 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from July 31, 2018. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:22 UTC |
Lynch Thomas GDirector
|
GrantStock option (right to buy) · Derivative | 0 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001618835-18-000076 · wf-form4_153324130486945.xml · derivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,500 Underlying: Common Stock · 85,500 shares Expires 2028-07-31 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from July 31, 2018. The option was awarded in connection with Mr. Lynch's consulting services. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:23 UTC |
Fitzpatrick Alexander AGeneral Counsel and Secretary
|
GrantStock option (right to buy) · Derivative | 0 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001618835-18-000077 · wf-form4_153324137208204.xml · derivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,500 Underlying: Common Stock · 104,500 shares Expires 2028-07-31 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from July 31, 2018. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:24 UTC |
Barrans RussellChief Commercial Officer
|
GrantStock option (right to buy) · Derivative | 98,800 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001618835-18-000078 · wf-form4_153324142399394.xml · derivative · entry 1 Barrans Russell · CIK 0001726184 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,800 Underlying: Common Stock · 98,800 shares Expires 2028-07-31 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from July 31, 2018. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:16 UTC |
Culwell KellyChief Medical Officer
|
GrantCommon Stock · Derivative | 98,800 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001618835-18-000074 · wf-form4_153324099080945.xml · derivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,800 Underlying: Common Stock · 98,800 shares Expires 2028-07-31 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from July 31, 2018. Read SEC document |
| July 24, 2018 Filed Jul 27, 2018 20:27 UTC |
O'Brien Anthony StephenDirector
|
GrantCommon Stock · Derivative | 12,875 | $0.00 Strike: $2.31 | $0.00 |
DisclosureSEC source: 0001618835-18-000052 · wf-form4_153272320631529.xml · derivative · entry 1 O'Brien Anthony Stephen · CIK 0001726732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,875 Underlying: Common Stock · 12,875 shares Expires 2028-07-24 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 8, 2018. The option was awarded in connection with Mr. O'Brien's board and committee services. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:59 UTC |
File Justin J.Chief Financial Officer
|
Tax withholdingCommon Stock | 119,510 | $2.46 | $293,994.60 |
DisclosureSEC source: 0001618835-18-000049 · wf-form4_153065157996681.xml · nonDerivative · entry 2 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,490 F2 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on July 2, 2018. No shares were sold in connection with this transaction. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:59 UTC |
File Justin J.Chief Financial Officer
|
GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-18-000049 · wf-form4_153065157996681.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 F1 · shares: The restricted stock awards vested in full on July 2, 2018. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:58 UTC |
PELLETIER SAUNDRA LDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 493,187 | $2.46 | $1,213,240.02 |
DisclosureSEC source: 0001618835-18-000048 · wf-form4_153065147716261.xml · nonDerivative · entry 2 PELLETIER SAUNDRA L · CIK 0001251371 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,813 F2 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on July 2, 2018. No shares were sold in connection with this transaction. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:58 UTC |
PELLETIER SAUNDRA LDirector · Chief Executive Officer
|
GrantCommon Stock | 825,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-18-000048 · wf-form4_153065147716261.xml · nonDerivative · entry 1 PELLETIER SAUNDRA L · CIK 0001251371 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 825,000 F1 · shares: The restricted stock awards vested in full on July 2, 2018. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:56 UTC |
Lynch Thomas GDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-18-000046 · wf-form4_153065134806235.xml · derivative · entry 3 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer dated April 1, 2016. F2 · derivative.exercise_date: The restricted stock units vested in full on July 2, 2018. F2 · derivative.expiration_date: The restricted stock units vested in full on July 2, 2018. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:56 UTC |
Lynch Thomas GDirector
|
GrantRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-18-000046 · wf-form4_153065134806235.xml · derivative · entry 2 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer dated April 1, 2016. F2 · derivative.exercise_date: The restricted stock units vested in full on July 2, 2018. F2 · derivative.expiration_date: The restricted stock units vested in full on July 2, 2018. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:56 UTC |
Lynch Thomas GDirector
|
Exercise / conversionCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-18-000046 · wf-form4_153065134806235.xml · nonDerivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer dated April 1, 2016. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:57 UTC |
Fitzpatrick Alexander AGeneral Counsel and Secretary
|
GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-18-000047 · wf-form4_153065141230310.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · shares: The restricted stock awards vest in two equal installments on each of October 16, 2018 and 2019 subject to Mr. Fitzpatrick's continued employment. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 21:03 UTC |
Barrans RussellChief Commercial Officer
|
Tax withholdingCommon Stock | 2,840 | $2.46 | $6,986.40 |
DisclosureSEC source: 0001618835-18-000050 · wf-form4_153065177824486.xml · nonDerivative · entry 2 Barrans Russell · CIK 0001726184 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,826 F2 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on July 2, 2018. No shares were sold in connection with this transaction. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 21:03 UTC |
Barrans RussellChief Commercial Officer
|
GrantCommon Stock | 11,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-18-000050 · wf-form4_153065177824486.xml · nonDerivative · entry 1 Barrans Russell · CIK 0001726184 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,666 F1 · shares: The restricted stock awards vested in full on July 2, 2018. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 20:54 UTC |
Culwell KellyChief Medical Officer
|
Tax withholdingCommon Stock | 4,748 | $2.46 | $11,680.08 |
DisclosureSEC source: 0001618835-18-000045 · wf-form4_153065127305105.xml · nonDerivative · entry 2 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,985 F2 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on July 2, 2018. No shares were sold in connection with this transaction. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 20:54 UTC |
Culwell KellyChief Medical Officer
|
GrantCommon Stock | 13,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-18-000045 · wf-form4_153065127305105.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,733 F1 · shares: The restricted stock awards vested in full on July 2, 2018. Read SEC document |
| May 22, 2018 Filed May 24, 2018 19:32 UTC |
Invesco Ltd.10% owner
|
PurchaseWarrants · Derivative | 2,127,659 | $0.01 Strike: $7.50 | $21,276.59 |
DisclosureSEC source: 0001209191-18-032950 · doc4.xml · derivative · entry 2 Invesco Ltd. · CIK 0000914208 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes (2), (3) and (4) Disclosed balance after: 2,127,659 Underlying: Common stock · 425,531 shares Expires 2018-05-24 F1 · kind: The common stock and warrants were purchased from the underwriters in a public offering pursuant to a registration statement on Form S-1 (333- 224958). The shares of common stock and warrants were purchased at the public offering price. Read SEC document |
| May 22, 2018 Filed May 24, 2018 19:32 UTC |
Invesco Ltd.10% owner
|
PurchaseCommon stock, Par value $0.0001 per share | 2,127,659 | $4.69 | $9,978,720.71 |
DisclosureSEC source: 0001209191-18-032950 · doc4.xml · nonDerivative · entry 1 Invesco Ltd. · CIK 0000914208 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 9,165,157 F1 · kind: The common stock and warrants were purchased from the underwriters in a public offering pursuant to a registration statement on Form S-1 (333- 224958). The shares of common stock and warrants were purchased at the public offering price. F2 · ownership.nature: Invesco Ltd. is the beneficial owner of 9,165,157 shares of common stock and 2,127,659 warrants acquired by its affiliates, Invesco Perpetual High Income Funda and Invesco Perpetual Income Fund. F3 · ownership.nature: Invesco Asset Management Ltd. is a subsidiary of Invesco Ltd., and it advises Invesco Perpetual High Income Fund and Invesco Perpetual Income Fund. F4 · ownership.nature: As described in the Neothetics, Inc. Registration Statement on Form S-4 (File No. 333-221592) voting and investment power over the common stock and warrants held by Invesco Perpetual High Income Fund and Invesco Perpetual Income Fund is exercised by the directors of Invesco Asset Management Ltd. Neothetics, Inc. changed its name to Evofem Biosciences, Inc. on January 17, 2017. Read SEC document |
| May 08, 2018 Filed May 9, 2018 18:23 UTC |
Rutherford ColinDirector
|
GrantStock option (right to buy) · Derivative | 12,875 | $0.00 Strike: $6.99 | $0.00 |
DisclosureSEC source: 0001618835-18-000016 · wf-form4_152590457623695.xml · derivative · entry 1 Rutherford Colin · CIK 0001726264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,875 Underlying: Common Stock · 12,875 shares Expires 2028-05-08 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 8, 2018. The option was awarded in connection with Mr. Rutherford's board and committee services. Read SEC document |
| May 08, 2018 Filed May 9, 2018 18:21 UTC |
Hall William WalmsleyDirector
|
GrantStock option (right to buy) · Derivative | 12,875 | $0.00 Strike: $6.99 | $0.00 |
DisclosureSEC source: 0001618835-18-000014 · wf-form4_152590442736853.xml · derivative · entry 1 Hall William Walmsley · CIK 0001726731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,875 Underlying: Common Stock · 12,875 shares Expires 2028-05-08 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 8, 2018. The option was awarded in connection with Dr. Hall's board and committee services. Read SEC document |
| May 08, 2018 Filed May 9, 2018 18:37 UTC |
Greer GillianDirector
|
GrantStock option (right to buy) · Derivative | 12,875 | $0.00 Strike: $6.99 | $0.00 |
DisclosureSEC source: 0001618835-18-000020 · wf-form4_152590542956608.xml · derivative · entry 1 Greer Gillian · CIK 0001726181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,875 Underlying: Common Stock · 12,875 shares Expires 2028-05-08 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 8, 2018. The option was awarded in connection with Dr. Greer's board and committee services. Read SEC document |
| May 08, 2018 Filed May 9, 2018 18:35 UTC |
Lynch Thomas GDirector
|
GrantStock option (right to buy) · Derivative | 12,875 | $0.00 Strike: $6.99 | $0.00 |
DisclosureSEC source: 0001618835-18-000018 · wf-form4_152590524333829.xml · derivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,875 Underlying: Common Stock · 12,875 shares Expires 2028-05-08 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 8, 2018. The option was awarded in connection with Mr. Lynch's board and committee services. Read SEC document |
| May 08, 2018 Filed May 10, 2018 22:08 UTC |
Kamdar Kim P.Director
|
GrantStock Option (Right to Buy) · Derivative | 12,875 | $0.00 Strike: $6.99 | $0.00 |
DisclosureSEC source: 0000904454-18-000341 · edgar.xml · derivative · entry 1 Kamdar Kim P. · CIK 0001535065 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,875 Underlying: Common Stock · 12,875 shares Expires 2028-05-08 F1 · derivative.exercise_date: The option vests in full on May 8, 2019, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 17:16 UTC |
File Justin J.Chief Financial Officer
|
GrantStock option (right to buy) · Derivative | 300,000 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019636 · doc4.xml · derivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-03-12 F1 · derivative.exercise_date: Mr. File acquired a vested interest in 66.67% of the shares of common stock exercisable pursuant to the option effective as of March 12, 2018 (the "Vesting Start Date"). The remaining shares shall vest in a series of twelve (12) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from the Vesting Start Date. The option was awarded in connection with Mr. File's service as Chief Financial Officer. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:15 UTC |
Rutherford ColinDirector
|
GrantStock option (right to buy) · Derivative | 24,691 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019694 · doc4.xml · derivative · entry 2 Rutherford Colin · CIK 0001726264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,691 Underlying: Common Stock · 24,691 shares Expires 2028-03-12 F2 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from March 12, 2018. The option was awarded in connection with Mr. Rutherford's board and committee services. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:15 UTC |
Rutherford ColinDirector
|
GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019694 · doc4.xml · derivative · entry 1 Rutherford Colin · CIK 0001726264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-03-12 F1 · derivative.exercise_date: Mr. Rutherford acquired a vested interest in one hundred percent (100%) of the shares of common stock exercisable pursuant to the option effective as of March 12, 2018. The option was awarded in connection with Mr. Rutherford's board and committee services. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 18:13 UTC |
Hall William WalmsleyDirector
|
GrantStock option (right to buy) · Derivative | 24,691 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019667 · doc4.xml · derivative · entry 1 Hall William Walmsley · CIK 0001726731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,691 Underlying: Common Stock · 24,691 shares Expires 2028-03-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from March 12, 2018. The option was awarded in connection with Dr. Hall's board and committee services. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 17:57 UTC |
Greer GillianDirector
|
GrantStock option (right to buy) · Derivative | 24,691 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019663 · doc4.xml · derivative · entry 1 Greer Gillian · CIK 0001726181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,691 Underlying: Common Stock · 24,691 shares Expires 2028-03-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from March 12, 2018. The option was awarded in connection with Dr. Greer's board and committee services. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:13 UTC |
PELLETIER SAUNDRA LDirector · Chief Executive Officer
|
GrantStock option (right to buy) · Derivative | 825,000 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019687 · doc4.xml · derivative · entry 1 PELLETIER SAUNDRA L · CIK 0001251371 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 825,000 Underlying: Common Stock · 825,000 shares Expires 2028-03-12 F1 · derivative.exercise_date: Ms. Pelletier acquired a vested interest in 66.67% of the shares of common stock exercisable pursuant to the option effective as of March 12, 2018 (the "Vesting Start Date"). The remaining shares shall vest in a series of twelve (12) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from the Vesting Commencement Date. The option was awarded in connection with Ms. Pelletier's service as President and Chief Executive Officer. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 18:17 UTC |
Lynch Thomas GDirector
|
GrantStock option (right to buy) · Derivative | 225,000 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019671 · doc4.xml · derivative · entry 2 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2028-03-12 F2 · derivative.exercise_date: Mr. Lynch acquired a vested interest in one hundred twenty-five thousand (125,000) shares of common stock exercisable pursuant to the option effective as of March 12, 2018. The remaining shares shall vest in a series of twelve (12) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from April 1, 2018. The option was awarded in connection with Mr. Lynch's consulting services provided to the Issuer. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 18:17 UTC |
Lynch Thomas GDirector
|
GrantStock option (right to buy) · Derivative | 24,691 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019671 · doc4.xml · derivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,691 Underlying: Common Stock · 24,691 shares Expires 2028-03-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from March 12, 2018. The option was awarded in connection with Mr. Lynch's board services. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 17:19 UTC |
Fitzpatrick Alexander AGeneral Counsel and Secretary
|
GrantStock option (right to buy) · Derivative | 275,000 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019640 · doc4.xml · derivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2028-03-12 F1 · derivative.exercise_date: Mr. Fitzpatrick acquired a vested interest in 25% of the shares of common stock exercisable pursuant to the option effective as of March 12, 2018 (the "Vesting Start Date"). The remaining shares shall vest in a series of twenty-four (24) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from the Vesting Start Date. The option was awarded in connection with Mr. Fitzpatrick's service as Secretary and General Counsel. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 00:18 UTC |
O'Brien Anthony StephenDirector
|
GrantStock option (right to buy) · Derivative | 24,691 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019705 · doc4.xml · derivative · entry 1 O'Brien Anthony Stephen · CIK 0001726732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,691 Underlying: Common Stock · 24,691 shares Expires 2028-03-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from March 12, 2018. The option was awarded in connection with Mr. O'Brien's board and committee services. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 21:16 UTC |
Culwell KellyChief Medical Officer
|
GrantStock option (right to buy) · Derivative | 260,000 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019635 · doc4.xml · derivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2028-03-12 F1 · derivative.exercise_date: Dr. Culwell acquired a vested interest in 66.67% of the shares of common stock exercisable pursuant to the option effective as of March 12, 2018 (the "Vesting Start Date"). The remaining shares shall vest in a series of twelve (12) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from the Vesting Start Date. The option was awarded in connection with Dr. Culwell's service as Chief Medical Officer. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 21:12 UTC |
Barrans RussellChief Commercial Officer
|
GrantStock option (right to buy) · Derivative | 260,000 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019632 · doc4.xml · derivative · entry 1 Barrans Russell · CIK 0001726184 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2028-03-12 F1 · derivative.exercise_date: Mr. Barrans acquired a vested interest in 66.67% of the shares of common stock exercisable pursuant to the option effective as of March 12, 2018 (the "Vesting Start Date"). The remaining shares shall vest in a series of twelve (12) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from the Vesting Start Date. The option was awarded in connection with Mr. Barrans' service as Chief Commercial Officer. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 17:09 UTC |
Rutherford ColinDirector
|
GrantStock Option (right to buy) · Derivative | 770 | Not disclosed Strike: $43.64 | Not disclosed |
DisclosureSEC source: 0001209191-18-004311 · doc4.xml · derivative · entry 1 Rutherford Colin · CIK 0001726264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 770 Underlying: Common Stock · 770 shares Expires 2027-03-08 F1 · shares: On January 17, 2018, Issuer completed a merger transaction (the "Merger") pursuant to an Agreement and Plan of Merger and Reorganization, dated October 17, 2017, by and among Issuer, Nobelli Merger Sub, Inc., and Evofem Biosciences Operations, Inc., formerly known as Evofem Biosciences, Inc. ("Evofem Operations"), as filed with the Securities and Exchange Commission on Form 8-K on October 17, 2017 (the "Merger Agreement"). Pursuant to the Merger Agreement all issued and outstanding options of Evofem Operations converted into and became options to purchase shares of Issuer's common stock. F2 · shares: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F2 · price: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F3 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option effective as of March 8, 2017 shall vest in a series of thirty-six (36) successive equal monthly installments commencing on February 12, 2017, such that all shares of common stock of Issuer exercisable pursuant to the option shall be fully vested on January 12, 2020, subject to Mr. Rutherford's continued service. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 17:03 UTC |
File Justin J.Chief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 10,266 | Not disclosed Strike: $46.36 | Not disclosed |
DisclosureSEC source: 0001209191-18-004299 · doc4.xml · derivative · entry 2 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,266 Underlying: Common Stock · 10,266 shares Expires 2026-09-28 F1 · shares: On January 17, 2018, Issuer completed a merger transaction (the "Merger") pursuant to an Agreement and Plan of Merger and Reorganization, dated October 17, 2017, by and among Issuer, Nobelli Merger Sub, Inc., and Evofem Biosciences Operations, Inc., formerly known as Evofem Biosciences, Inc. ("Evofem Operations"), as filed with the Securities and Exchange Commission on Form 8-K on October 17, 2017 (the "Merger Agreement"). Pursuant to the Merger Agreement all issued and outstanding options of Evofem Operations converted into and became options to purchase shares of Issuer's common stock. F2 · shares: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase up to 900,000 shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F2 · price: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase up to 900,000 shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F4 · derivative.exercise_date: Mr. File acquired a vested interest in twenty-five percent (25%) of the shares of common stock exercisable pursuant to the option effective as of September 28, 2017 (the "Vesting Start Date"). The remaining shares shall vest in a series of thirty-six (36) successive equal monthly installments on the monthly anniversary of the Vesting Start Date, such that all shares of common stock of Issuer exercisable pursuant to the option shall be fully vested on September 28, 2020, subject to Mr. File's continued service. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 17:03 UTC |
File Justin J.Chief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 12,833 | Not disclosed Strike: $46.36 | Not disclosed |
DisclosureSEC source: 0001209191-18-004299 · doc4.xml · derivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,833 Underlying: Common Stock · 12,833 shares Expires 2026-09-28 F1 · shares: On January 17, 2018, Issuer completed a merger transaction (the "Merger") pursuant to an Agreement and Plan of Merger and Reorganization, dated October 17, 2017, by and among Issuer, Nobelli Merger Sub, Inc., and Evofem Biosciences Operations, Inc., formerly known as Evofem Biosciences, Inc. ("Evofem Operations"), as filed with the Securities and Exchange Commission on Form 8-K on October 17, 2017 (the "Merger Agreement"). Pursuant to the Merger Agreement all issued and outstanding options of Evofem Operations converted into and became options to purchase shares of Issuer's common stock. F2 · shares: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase up to 900,000 shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F2 · price: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase up to 900,000 shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F3 · derivative.exercise_date: Mr. File acquired a vested interest in twenty-five percent (25%) of the shares of common stock exercisable pursuant to the option effective as of September 28, 2016 (the "Vesting Start Date"). The remaining shares shall vest in a series of thirty-six (36) successive equal monthly installments on the monthly anniversary of the Vesting Start Date, such that all shares of common stock of Issuer exercisable pursuant to the option shall be fully vested on September 28, 2019, subject to Mr. File's continued service. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 17:07 UTC |
PELLETIER SAUNDRA LDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 6,719 | Not disclosed Strike: $79.87 | Not disclosed |
DisclosureSEC source: 0001209191-18-004307 · doc4.xml · derivative · entry 4 PELLETIER SAUNDRA L · CIK 0001251371 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,719 Underlying: Common Stock · 6,719 shares Expires 2023-06-03 F1 · shares: On January 17, 2018, Issuer completed a merger transaction (the "Merger") pursuant to an Agreement and Plan of Merger and Reorganization, dated October 17, 2017, by and among Issuer, Nobelli Merger Sub, Inc., and Evofem Biosciences Operations, Inc., formerly known as Evofem Biosciences, Inc. ("Evofem Operations"), as filed with the Securities and Exchange Commission on Form 8-K on October 17, 2017 (the "Merger Agreement"). Pursuant to the Merger Agreement all issued and outstanding options of Evofem Operations converted into and became options to purchase shares of Issuer's common stock. F2 · shares: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F2 · price: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F6 · derivative.exercise_date: Ms. Pelletier acquired a vested interest in one hundred percent (100%) of the shares of common stock exercisable pursuant to the option effective as of June 3, 2013. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 17:07 UTC |
PELLETIER SAUNDRA LDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 9,994 | Not disclosed Strike: $46.36 | Not disclosed |
DisclosureSEC source: 0001209191-18-004307 · doc4.xml · derivative · entry 3 PELLETIER SAUNDRA L · CIK 0001251371 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,994 Underlying: Common Stock · 9,994 shares Expires 2026-09-28 F1 · shares: On January 17, 2018, Issuer completed a merger transaction (the "Merger") pursuant to an Agreement and Plan of Merger and Reorganization, dated October 17, 2017, by and among Issuer, Nobelli Merger Sub, Inc., and Evofem Biosciences Operations, Inc., formerly known as Evofem Biosciences, Inc. ("Evofem Operations"), as filed with the Securities and Exchange Commission on Form 8-K on October 17, 2017 (the "Merger Agreement"). Pursuant to the Merger Agreement all issued and outstanding options of Evofem Operations converted into and became options to purchase shares of Issuer's common stock. F2 · shares: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F2 · price: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F5 · derivative.exercise_date: Ms. Pelletier acquired a vested interest in one hundred percent (100%) of the shares of common stock exercisable pursuant to the option effective as of September 28, 2016. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 17:07 UTC |
PELLETIER SAUNDRA LDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 12,833 | Not disclosed Strike: $46.36 | Not disclosed |
DisclosureSEC source: 0001209191-18-004307 · doc4.xml · derivative · entry 2 PELLETIER SAUNDRA L · CIK 0001251371 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,833 Underlying: Common Stock · 12,833 shares Expires 2026-09-28 F1 · shares: On January 17, 2018, Issuer completed a merger transaction (the "Merger") pursuant to an Agreement and Plan of Merger and Reorganization, dated October 17, 2017, by and among Issuer, Nobelli Merger Sub, Inc., and Evofem Biosciences Operations, Inc., formerly known as Evofem Biosciences, Inc. ("Evofem Operations"), as filed with the Securities and Exchange Commission on Form 8-K on October 17, 2017 (the "Merger Agreement"). Pursuant to the Merger Agreement all issued and outstanding options of Evofem Operations converted into and became options to purchase shares of Issuer's common stock. F2 · shares: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F2 · price: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F4 · derivative.exercise_date: Ms. Pelletier acquired a vested interest in twenty-five percent (25%) of the shares of common stock exercisable pursuant to the option effective as of September 28, 2017 (the "Vesting Start Date"). The remaining shares shall vest in a series of thirty-six (36) successive equal monthly installments on the monthly anniversary of the Vesting Start Date, such that all shares of common stock of Issuer exercisable pursuant to the option shall be fully vested on September 28, 2020, subject to Ms. Pelletier's continued service. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 17:07 UTC |
PELLETIER SAUNDRA LDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 19,249 | Not disclosed Strike: $46.36 | Not disclosed |
DisclosureSEC source: 0001209191-18-004307 · doc4.xml · derivative · entry 1 PELLETIER SAUNDRA L · CIK 0001251371 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,249 Underlying: Common Stock · 19,249 shares Expires 2026-09-28 F1 · shares: On January 17, 2018, Issuer completed a merger transaction (the "Merger") pursuant to an Agreement and Plan of Merger and Reorganization, dated October 17, 2017, by and among Issuer, Nobelli Merger Sub, Inc., and Evofem Biosciences Operations, Inc., formerly known as Evofem Biosciences, Inc. ("Evofem Operations"), as filed with the Securities and Exchange Commission on Form 8-K on October 17, 2017 (the "Merger Agreement"). Pursuant to the Merger Agreement all issued and outstanding options of Evofem Operations converted into and became options to purchase shares of Issuer's common stock. F2 · shares: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F2 · price: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F3 · derivative.exercise_date: Ms. Pelletier acquired a vested interest in twenty-five percent (25%) of the shares of common stock exercisable pursuant to the option effective as of September 28, 2016 (the "Vesting Start Date"). The remaining shares shall vest in a series of thirty-six (36) successive equal monthly installments on the monthly anniversary of the Vesting Start Date, such that all shares of common stock of Issuer exercisable pursuant to the option shall be fully vested on September 28, 2019, subject to Ms. Pelletier's continued service. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 17:05 UTC |
Lynch Thomas GDirector
|
GrantStock Option (right to buy) · Derivative | 3,850 | Not disclosed Strike: $46.36 | Not disclosed |
DisclosureSEC source: 0001209191-18-004303 · doc4.xml · derivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,850 Underlying: Common Stock · 3,850 shares Expires 2026-10-13 F1 · shares: On January 17, 2018, Issuer completed a merger transaction (the "Merger") pursuant to an Agreement and Plan of Merger and Reorganization, dated October 17, 2017, by and among Issuer, Nobelli Merger Sub, Inc., and Evofem Biosciences Operations, Inc., formerly known as Evofem Biosciences, Inc. ("Evofem Operations"), as filed with the Securities and Exchange Commission on Form 8-K on October 17, 2017 (the "Merger Agreement"). Pursuant to the Merger Agreement all issued and outstanding options of Evofem Operations converted into and became options to purchase shares of Issuer's common stock. F2 · shares: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F2 · price: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F3 · derivative.exercise_date: Mr. Lynch's interest in the shares of common stock exercisable pursuant to the option effective as of October 13, 2016 vested in a series of twenty-four (24) successive equal monthly installments commencing on April 1, 2016, such that all shares of common stock of Issuer exercisable pursuant to the option were fully vested as of March 1, 2017. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 22:01 UTC |
Culwell KellyChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 7,699 | Not disclosed Strike: $46.36 | Not disclosed |
DisclosureSEC source: 0001209191-18-004295 · doc4.xml · derivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,699 Underlying: Common Stock · 7,699 shares Expires 2026-09-28 F1 · shares: On January 17, 2018, Issuer completed a merger transaction (the "Merger") pursuant to an Agreement and Plan of Merger and Reorganization, dated October 17, 2017, by and among Issuer, Nobelli Merger Sub, Inc., and Evofem Biosciences Operations, Inc., formerly known as Evofem Biosciences, Inc. ("Evofem Operations"), as filed with the Securities and Exchange Commission on Form 8-K on October 17, 2017 (the "Merger Agreement"). Pursuant to the Merger Agreement all issued and outstanding options of Evofem Operations converted into and became options to purchase shares of Issuer's common stock. F2 · shares: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F2 · price: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F3 · derivative.exercise_date: Dr. Culwell acquired a vested interest in twenty-five percent (25%) of the shares of common stock exercisable pursuant to the option effective as of September 28, 2016 (the "Vesting Start Date"). The remaining shares shall vest in a series of thirty-six (36) successive equal monthly installments on the monthly anniversary of the Vesting Start Date, such that all shares of common stock of Issuer exercisable pursuant to the option shall be fully vested on September 28, 2019, subject to Dr. Culwell's continued service. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 21:59 UTC |
Barrans RussellChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 1,283 | Not disclosed Strike: $46.36 | Not disclosed |
DisclosureSEC source: 0001209191-18-004293 · doc4.xml · derivative · entry 2 Barrans Russell · CIK 0001726184 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,283 Underlying: Common Stock · 1,283 shares Expires 2026-09-28 F1 · shares: On January 17, 2018, Issuer completed a merger transaction (the "Merger") pursuant to an Agreement and Plan of Merger and Reorganization, dated October 17, 2017, by and among Issuer, Nobelli Merger Sub, Inc., and Evofem Biosciences Operations, Inc., formerly known as Evofem Biosciences, Inc. ("Evofem Operations"), as filed with the Securities and Exchange Commission on Form 8-K on October 17, 2017 (the "Merger Agreement"). Pursuant to the Merger Agreement all issued and outstanding options of Evofem Operations converted into and became options to purchase shares of Issuer's common stock. F2 · shares: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F2 · price: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F4 · derivative.exercise_date: Mr. Barrans acquired a vested interest in twenty-five percent (25%) of the shares of common stock exercisable pursuant to the option effective as of September 28, 2017 (the "Vesting Start Date"). The remaining shares shall vest in a series of thirty-six (36) successive equal monthly installments on the monthly anniversary of the Vesting Start Date, such that all shares of common stock of Issuer exercisable pursuant to the option shall be fully vested on September 28, 2020, subject to Mr. Barrans' continued service. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 21:59 UTC |
Barrans RussellChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 3,850 | Not disclosed Strike: $46.36 | Not disclosed |
DisclosureSEC source: 0001209191-18-004293 · doc4.xml · derivative · entry 1 Barrans Russell · CIK 0001726184 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,850 Underlying: Common Stock · 3,850 shares Expires 2026-09-28 F1 · shares: On January 17, 2018, Issuer completed a merger transaction (the "Merger") pursuant to an Agreement and Plan of Merger and Reorganization, dated October 17, 2017, by and among Issuer, Nobelli Merger Sub, Inc., and Evofem Biosciences Operations, Inc., formerly known as Evofem Biosciences, Inc. ("Evofem Operations"), as filed with the Securities and Exchange Commission on Form 8-K on October 17, 2017 (the "Merger Agreement"). Pursuant to the Merger Agreement all issued and outstanding options of Evofem Operations converted into and became options to purchase shares of Issuer's common stock. F2 · shares: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F2 · price: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F3 · derivative.exercise_date: Mr. Barrans acquired a vested interest in twenty-five percent (25%) of the shares of common stock exercisable pursuant to the option effective as of September 28, 2016 (the "Vesting Start Date"). The remaining shares shall vest in a series of thirty-six (36) successive equal monthly installments on the monthly anniversary of the Vesting Start Date, such that all shares of common stock of Issuer exercisable pursuant to the option shall be fully vested on September 28, 2019, subject to Mr. Barrans' continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.